









Markets
/
Stocks
/
nasdaq-knsa
/

Kiniksa Pharmaceuticals International PLC

KNSA

40.677USD

+1.177+2.98%

Market hours （ET）Quotes delayed by 15 min

3.07BMarket Cap

85.42P/E TTM



Kiniksa Pharmaceuticals International PLC

40.677

+1.177+2.98%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kiniksa Pharmaceuticals International PLC

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kiniksa Pharmaceuticals International PLC's Score

Industry at a Glance

Industry Ranking

6 / 159

Overall Ranking

30 / 4611

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

54.000

Target Price

+40.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kiniksa Pharmaceuticals International PLC Highlights

StrengthsRisks

Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 92.22% year-on-year.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 81.22, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 40.93M shares, decreasing 8.74% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 848.55K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.07.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 9.36, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 180.85M, representing a year-over-year increase of 61.17%, while its net profit experienced a year-over-year increase of 245.24%.

Score

Industry at a Glance

Previous score

9.36

Change



Financials

9.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Kiniksa Pharmaceuticals International PLC's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 5.39, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 81.22, which is 713.18% below the recent high of 660.48 and 378.73% above the recent low of -226.39.

Score

Industry at a Glance

Previous score

5.39

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.86, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Kiniksa Pharmaceuticals International PLC is 55.00, with a high of 62.00 and a low of 45.00.

Score

Industry at a Glance

Previous score

8.86

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

54.000

Target Price

+40.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Kiniksa Pharmaceuticals International PLC

KNSA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 9.07, which is higher than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 42.63 and the support level at 35.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.41

Change

1.66

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.082

Neutral

RSI(14)

58.212

Neutral

STOCH(KDJ)(9,3,3)

69.083

Buy

ATR(14)

1.773

High Vlolatility

CCI(14)

73.921

Neutral

Williams %R

37.226

Buy

TRIX(12,20)

0.081

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

38.836

Buy

MA10

38.276

Buy

MA20

38.605

Buy

MA50

37.528

Buy

MA100

33.926

Buy

MA200

28.583

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 90.64%, representing a quarter-over-quarter decrease of 7.60%. The largest institutional shareholder is The Vanguard, holding a total of 3.06M shares, representing 6.77% of shares outstanding, with 11.40% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Rubric Capital Management LP

3.91M

+15.56%

The Vanguard Group, Inc.

Star Investors

3.12M

-6.74%

Baker Bros. Advisors LP

2.82M

+0.23%

Tang Capital Management, LLC

2.33M

+9.91%

Fairmount Funds Management LLC

1.77M

+60.84%

Acadian Asset Management LLC

1.27M

+22.59%

Braidwell LP

1.10M

-43.83%

Desnick (Robert)

1.05M

Millennium Management LLC

1.02M

+20.40%

Pictet Asset Management Ltd.

984.60K

-13.17%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 8.04, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.02. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.